Terumo (OTCMKTS:TRUMY) Shares Gap Up – Should You Buy?

Terumo Corp. (OTCMKTS:TRUMY – Get Free Report)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $12.18, but opened at $14.04. Terumo shares last traded at $14.4386, with a volume of 24,330 shares traded.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Zacks Research upgraded Terumo to a “hold” rating in a report on Thursday, April 9th. Nomura raised shares of Terumo to a “hold” rating in a research report on Tuesday, February 24th. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Get Terumo alerts:

View Our Latest Stock Report on Terumo

Terumo Trading Up 13.1%

The firm has a market capitalization of $21.15 billion, a price-to-earnings ratio of 23.51 and a beta of 0.62. The business has a 50-day moving average of $13.08 and a two-hundred day moving average of $13.98. The company has a quick ratio of 0.89, a current ratio of 1.51 and a debt-to-equity ratio of 0.07.

Terumo (OTCMKTS:TRUMY – Get Free Report) last released its earnings results on Friday, May 15th. The company reported $0.11 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.11. Terumo had a return on equity of 9.35% and a net margin of 12.09%.The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.84 billion. Research analysts predict that Terumo Corp. will post 0.63 EPS for the current fiscal year.

About Terumo

(Get Free Report)

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.

Featured Articles

• Five stocks we like better than Terumo
• Consumer-Driven Stocks Boost Buybacks, Including Visa’s $20B Plan
• Iran Ceasefire Trade: 3 Energy Stocks to Own if Oil Falls to $80
• Willing and Abel: Berkshire’s New CEO Makes Huge Portfolio Changes in Q1
• Insider Buying Says Upstart Isn’t Down for the Count

Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.